Ticker Report Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) was downgraded by equities researchers at StockNews.com from a "buy" rating to a "hold" rating in a research note issued on Tuesday. Separately...\n more…
Ticker Report Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) - HC Wainwright upped their Q3 2024 earnings estimates for Oramed Pharmaceuticals in a research note issued to investors on Monday, September...\n more…
Zolmax Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) - Investment analysts at Zacks Small Cap cut their Q3 2024 earnings per share estimates for Oramed Pharmaceuticals in a research report...\n more…